Trials / Completed
CompletedNCT04800315
A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects With Moderate to Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 221 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness and safety of 3 dose regimen of CC-93538 in adult participants with moderate to severe Atopic Dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-93538 | Specified dosages on specified days |
| OTHER | Placebo | Specified dosages on specified days |
Timeline
- Start date
- 2021-05-14
- Primary completion
- 2022-07-20
- Completion
- 2022-11-09
- First posted
- 2021-03-16
- Last updated
- 2024-01-03
- Results posted
- 2024-01-03
Locations
157 sites across 6 countries: United States, Canada, China, Czechia, Japan, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04800315. Inclusion in this directory is not an endorsement.